Overview
Infliximab is a chimeric monoclonal antibody that targets tumour necrosis factor-alpha (TNF-α), a key protein driving inflammation in IBD. It was the first biologic approved for Crohn's disease and ulcerative colitis and remains one of the most widely used. It is given as an intravenous infusion in a clinic or hospital setting.
Key Uses
Moderate-to-severe Crohn's disease (luminal and fistulising)
Moderate-to-severe ulcerative colitis
Crohn's fistulae (perianal disease)
Maintaining remission after steroid-induced response
Paediatric Crohn's disease and ulcerative colitis
How It Works
Binds and neutralises both soluble and membrane-bound TNF-α
Reduces mucosal inflammation and promotes healing of the intestinal lining
Induction: doses at weeks 0, 2, and 6; maintenance: every 8 weeks thereafter
Drug levels and antibody monitoring (therapeutic drug monitoring) guide dosing adjustments
Biosimilars (Remsima, Flixabi, Inflectra) are equally effective and widely available
Safety & Self-Care
Screen for tuberculosis (TB) and hepatitis B before starting — required
Report any signs of infection immediately: fever, chills, unusual cough, urinary symptoms
Avoid live vaccines while on infliximab; inactivated vaccines are generally safe
Infusion reactions can occur during or shortly after the infusion — staff are on hand to manage them
Do not stop treatment without discussing with your IMCC team — loss of response may occur
Regular monitoring: blood tests, TB screening, and clinical review every few months
Contact Your IMCC Team
Contact your IMCC team before any surgery, dental procedure, or new vaccine; if you develop fever, chills, or signs of infection; if symptoms worsen between infusions; or if you are planning a pregnancy.
Share this with someone who needs it: